Supernus Pharmaceuticals, Inc. $SUPN Shares Purchased by First Trust Advisors LP

First Trust Advisors LP boosted its stake in shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) by 56.4% in the 1st quarter, Holdings Channel reports. The fund owned 46,627 shares of the specialty pharmaceutical company’s stock after buying an additional 16,823 shares during the period. First Trust Advisors LP’s holdings in Supernus Pharmaceuticals were worth $2,410,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors also recently bought and sold shares of the stock. Sit Investment Associates Inc. grew its holdings in Supernus Pharmaceuticals by 0.4% in the 4th quarter. Sit Investment Associates Inc. now owns 65,200 shares of the specialty pharmaceutical company’s stock valued at $3,240,000 after buying an additional 250 shares in the last quarter. Summit Global Investments boosted its position in shares of Supernus Pharmaceuticals by 6.1% during the 1st quarter. Summit Global Investments now owns 4,436 shares of the specialty pharmaceutical company’s stock valued at $229,000 after acquiring an additional 256 shares during the last quarter. Maryland State Retirement & Pension System boosted its position in shares of Supernus Pharmaceuticals by 3.6% during the 4th quarter. Maryland State Retirement & Pension System now owns 8,351 shares of the specialty pharmaceutical company’s stock valued at $415,000 after acquiring an additional 290 shares during the last quarter. SummitTX Capital L.P. grew its holdings in shares of Supernus Pharmaceuticals by 2.7% in the fourth quarter. SummitTX Capital L.P. now owns 11,670 shares of the specialty pharmaceutical company’s stock valued at $580,000 after purchasing an additional 303 shares during the period. Finally, PNC Financial Services Group Inc. grew its holdings in shares of Supernus Pharmaceuticals by 2.3% in the first quarter. PNC Financial Services Group Inc. now owns 14,548 shares of the specialty pharmaceutical company’s stock valued at $752,000 after purchasing an additional 321 shares during the period.

Wall Street Analyst Weigh In

A number of equities analysts have commented on the stock. Weiss Ratings reaffirmed a “sell (d+)” rating on shares of Supernus Pharmaceuticals in a research note on Wednesday, June 24th. Wall Street Zen cut shares of Supernus Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Saturday. Zacks Research upgraded shares of Supernus Pharmaceuticals from a “strong sell” rating to a “hold” rating in a report on Monday, April 27th. Finally, Cantor Fitzgerald raised their price target on shares of Supernus Pharmaceuticals from $63.00 to $67.00 and gave the stock an “overweight” rating in a report on Thursday, July 9th. Four research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Hold” and an average price target of $62.83.

Supernus Pharmaceuticals Trading Up 1.9%

Shares of SUPN opened at $47.64 on Friday. The firm has a market cap of $2.77 billion, a P/E ratio of -24.81, a price-to-earnings-growth ratio of 0.76 and a beta of 0.56. Supernus Pharmaceuticals, Inc. has a 12-month low of $40.26 and a 12-month high of $59.68. The company’s 50-day moving average price is $46.17 and its 200 day moving average price is $48.93.

Supernus Pharmaceuticals Profile

Supernus Pharmaceuticals, Inc, headquartered in Rockville, Maryland, is a specialty pharmaceutical company dedicated to developing and commercializing central nervous system (CNS) therapies. Since its founding in 2003, Supernus has focused on advancing treatments for neurological disorders, with an emphasis on improving patient quality of life through innovative dosage forms and sustained‐release formulations.

The company’s marketed portfolio includes Trokendi XR and Oxtellar XR, extended‐release antiepileptic medications designed to maintain stable drug levels for seizure control, as well as Qelbree (viloxazine extended‐release capsules), approved for the treatment of attention‐deficit/hyperactivity disorder (ADHD) in pediatric and adult patients.